Nutrition & Care Q1 2021 Sales in both divisions of the Nutrition & Care segment declined slightly compared with the prior-year quarter. (XLSX:) XLS Factors influencing sales in Q1 2021 – Nutrition & Care Nutrition & Care Care Chemicals Nutrition & Health Volumes 3% 2% 4% Prices –1% 0% –3% Portfolio 0% 0% 0% Currencies –5% –5% –5% Sales –3% –3% –4% The development of sales primarily reflected negative currency effects, mainly relating to the U.S. dollar. Sales were negatively impacted by slightly lower price levels overall. This mainly resulted from lower prices in the Nutrition & Health division, especially in the aroma ingredients and animal nutrition businesses. In the Care Chemicals division, prices were on a level with the prior-year quarter. Higher prices in the oleo surfactants and fatty alcohols business compensated for lower prices in the other business areas. Sales volumes were slightly above the prior-year quarter in both divisions. In the Care Chemicals division, higher volumes in the home care, industrial and institutional cleaning and industrial formulators business more than compensated for lower volumes in the other business areas. The Nutrition & Health division recorded significantly higher volumes in the aroma ingredients and pharmaceutical businesses. This was partially offset by significantly lower sales volumes in the animal nutrition business. Income from operations (EBIT) before special items decreased considerably compared with the prior-year quarter. The decline in earnings impacted both divisions and primarily reflected lower margins as a result of lower sales. (XLSX:) XLS Segment data – Nutrition & Care (Million €) Q1 2021 2020 +/– Sales to third parties 1,533 1,582 –3% of which Care Chemicals 1,059 1,088 –3% Nutrition & Health 474 494 –4% Income from operations before depreciation, amortization and special items 316 357 –11% Income from operations before depreciation and amortization (EBITDA) 313 352 –11% EBITDA margin % 20.4 22.3 − Depreciation and amortizationa 98 108 –9% Income from operations (EBIT) 215 244 –12% Special items –3 –10 70% EBIT before special items 218 254 –14% Assets (March 31) 6,579 6,546 1% Investments including acquisitionsb 100 102 –2% Research and development expenses 40 37 8% a Depreciation and amortization of property, plant and equipment and intangible assets (including impairments and reversals of impairments) b Additions to property, plant and equipment and intangible assets back next